NCT05605301View on ClinicalTrials.gov

Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagnosis of Epilepsy

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

September 2, 2022

Primary Completion Date

February 5, 2024

Study Completion Date

February 5, 2024

Conditions
Epilepsy; Seizure
Interventions
DRUG

Oral 2-Deoxy-D-Glucose (2DG)

2DG will be formulated as an solid dosage form and administered orally.

Trial Locations (1)

22908

University of Virginia School of Medicine, Charlottesville

All Listed Sponsors
collaborator

Epilepsy Foundation

OTHER

collaborator

University of Wisconsin, Madison

OTHER

lead

University of Virginia

OTHER